CorMedix, Inc. (CRMD) Stock: Seeing Gains In Today’s Session


CorMedix, Inc. (CRMD) is making a move up in the market today. The stock, focused in the biotechnology space, is presently trading at $7.33 after gaining 8.75% so far today. In terms of biotech stocks, there are several aspects that have the potential to cause gains in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories associated with CRMD:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-16-19 08:45AM CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
May-13-19 10:28PM Edited Transcript of CRMD earnings conference call or presentation 13-May-19 8:30pm GMT
05:45PM CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
04:41PM CorMedix: 1Q Earnings Snapshot
04:05PM CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

However, when making a decision to invest, prospective investors should look into much more than just news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening in regard to CorMedix, Inc..

Trends That We’ve Seen From CRMD

While a single session gain, like what we’re seeing from CorMedix, Inc. may cause excitement in some investors, a single session move alone should not be the reason for a decision to, or not to, buy a company’s stock. It’s always smart to dig into trends for a period longer than a single trading session. In the case of CRMD, here are the movements that we’ve seen:

  • Past 5 Sessions – Throughout the last 5 trading sessions, CRMD has produced a change in value that amounts to -0.41%.
  • Past Month – The performance from CorMedix, Inc. in the last 30 days has been -13.25%.
  • Quarterly – In the past 3 months, the stock has generated a return that works out to -13.25%
  • Bi-Annually – Throughout the last 6 months, investors have seen a performance that works out to 33.27% from the company.
  • Year To Date – Since the open of this year CRMD has generated a return of 13.64%.
  • Full Year – Finally, over the past full year, investors have seen performance in the amount of 671.58% out of CRMD. In this period, the stock has sold at a high of -46.50% and a low of 751.83%.

Rations That You Should Look Into

Looking at various ratios having to do with a stock can provide investors a look of just how risky and/or rewarding a pick might be. Below are some of the most important ratios to think about when digging into CRMD.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the level of short interest. As the ratio heads up, it means that more investors have a belief that the value of the stock is going to tumble. Across the sector, biotech stocks can come with a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, when it comes to CorMedix, Inc., the stock’s short ratio comes to 7.23.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure whether or not a company can pay for its debts as they mature based on current assets or quick assets. Because many biotech many companies rely heavily on continued support from investors, these ratios can seem bad. However, several gems in the biotechnology space do have great current and quick ratios. In terms of CRMD, the quick and current ratios work out to 6.20 and 6.30 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In this case, the book to share value ratio equates to 0.72.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotech space, this is a very important ratio to consider. In this case, the cash to share value is 1.14.

What Analysts Say About CorMedix, Inc.

While it’s rarely a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their opinions to validate your own when it comes to making an investment decision in the biotechnology sector. Here are the most recent moves that we have seen from analysts when it comes to CRMD.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-26-19 Reiterated H.C. Wainwright Buy $3 → $15
Dec-06-18 Initiated ROTH Capital Buy $6
Sep-25-17 Reiterated H.C. Wainwright Buy $3 → $4
Aug-10-17 Reiterated Rodman & Renshaw Buy $5 → $3
May-05-17 Reiterated Rodman & Renshaw Buy $6 → $5

What Are Big Money Players Doing With CorMedix, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CRMD, here’s what we’re seeing:

Institutions own 16.70% of the company. Institutional interest has moved by 24.85% over the past three months. When it comes to insiders, those who are close to the company currently own 1.30% percent of CRMD shares. Institutions have seen ownership changes of an accumulative 205.27% over the last three months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 23.07M shares of CorMedix, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CRMD has a float of 22.76M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CRMD, the short percent of the float is 15.48%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.63. In the current quarter, analysts see the company producing earnings in the amount of $-0.25. Over the last 5 years, CRMD has generated revenue in the amount of $192.70% with earnings coming in at 15.20%. On a quarter over quarter basis, earnings have seen movement of 66.90% and revenue has seen movement of 605.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here